| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $41.2M | -52.3% |
| R&D Expense | $225.9M | -36.6% |
| SG&A Expense | $216.4M | -21.2% |
| Operating Income | -$432.4M | +25.4% |
| Pre-tax Income | -$400.7M | +26.0% |
| Net Income | -$400.7M | +26.0% |
| EPS (Basic) | -$6.59 | +27.2% |
| EPS (Diluted) | -$6.59 | +27.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $81.0M | +14.1% |
| Short-term Investments | $423.4M | -37.9% |
| Accounts Receivable | $9.1M | -89.0% |
| Current Assets | $531.3M | -38.9% |
| Total Assets | $547.2M | -38.0% |
| Current Liabilities | $71.6M | -13.5% |
| Total Liabilities | $82.1M | -0.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$267.2M | +50.6% |
| Capital Expenditures | $0 | -100.0% |
| Investing Cash Flow | $266.7M | -39.8% |
| Financing Cash Flow | $10.7M | +76.9% |
| Free Cash Flow | -$267.2M | +50.6% |
| Stockholders' Equity |
| $465.1M |
| -41.8% |